AIM: In clinical studies, imiquimod 3.75% was shown to detect and treat @entity2517 ( @entity2517 ) lesions across an entire sun-exposed field such as the full face or balding scalp. The aim of this study was to evaluate imiquimod 3.75% in a real-life clinical setting. METHODS: Ten @entity2517 @entity1 applied imiquimod 3.75% to the full face or scalp once- daily in two 2-week treatment cycles separated by a two-week treatment-free interval and were followed-up eight weeks later. Seven @entity1 rated imiquimod 3.75% versus prior treatments (cryotherapy, photodynamic therapy, @entity3522 3%, imiquimod 5%, @entity32990 ). RESULTS: The median clinical lesion count at baseline was 12.5. This increased to a median Lmax (maximum lesion count during treatment) of 22.5 as imiquimod 3.75% unmasked previously invisible subclinical lesions. At final follow-up, the median lesion count was zero. Local skin reactions such as erythema, scabbing and @entity2681 occurred during each treatment cycle and were easy to manage. All @entity1 considered imiquimod 3.75% easier to apply than prior treatments and five reported fewer or similar side effects. CONCLUSION: In this cohort, imiquimod 3.75% effectively cleared clinical and subclinical lesions across the entire affected field and was well tolerated.

Clinical experience of imiquimod 3.75% for XXXX : results from a case series.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity3522 :: ('MESH:D004008', 'Chemical') :: ['diclofenac sodium'] @entity2517 :: ('MESH:D055623', 'Disease') :: ['AK', 'actinic keratosis'] @entity2681 :: ('MESH:D014077', 'Disease') :: ['erosion'] @entity32990 :: ('MESH:C486592', 'Chemical') :: ['ingenol mebutate']
@entity2517 :: (MESH:D055623,Disease) :: ['actinic keratosis']
